Meridian Bioscience, Inc. (VIVO)
Stock Price Chart
Key Info
| Market Cap | 785.67M |
| Revenue (ttm) | 240.36M |
| Net Income (ttm) | 43.80M |
| Shares Out | 42.86M |
| EPS (ttm) | 1.02 |
| PE Ratio | 17.97 |
| Forward PE | 16.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $18.33 |
| Previous Close | $18.32 |
| Change ($) | 0.01 |
| Change (%) | 0.05% |
| Day's Open | 18.44 |
| Day's Range | 17.84 - 18.44 |
| Day's Volume | 208,352 |
| 52-Week Range | 5.51 - 26.58 |
More Stats
| Market Cap | 785.67M |
| Enterprise Value | 838.94M |
| Earnings Date (est) | Nov 13, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 42.86M |
| Float | 42.11M |
| EPS (basic) | 1.02 |
| EPS (diluted) | 1.02 |
| FCF / Share | 0.86 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 5.56% |
| FCF Yield | 4.69% |
| Payout Ratio | n/a |
| Shares Short | 2.92M |
| Short Ratio | 4.09 |
| Short % of Float | 6.94% |
| Beta | 0.60 |
| PE Ratio | 17.97 |
| Forward PE | 16.67 |
| P/FCF Ratio | 21.30 |
| PS Ratio | 3.27 |
| PB Ratio | 3.37 |
| Revenue | 240.36M |
| Operating Income | 57.70M |
| Net Income | 43.80M |
| Free Cash Flow | 36.88M |
| Net Cash | -53.27M |
| Net Cash / Share | -1.24 |
| Gross Margin | 49.23% |
| Operating Margin | 24.01% |
| Profit Margin | 18.20% |
| FCF Margin | 15.34% |
| ROA | 9.64% |
| ROE | 20.76% |
| ROIC | 33.90% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 201 | 214 | 201 | 196 | 195 | 189 | 189 | 173 | 159 | 143 |
| Revenue Growth | -5.88% | 6.38% | 2.39% | 0.64% | 3.18% | 0.08% | 9.25% | 8.74% | 11.07% | - |
| Gross Profit | 118 | 131 | 124 | 127 | 122 | 117 | 121 | 109 | 98.41 | 88.70 |
| Operating Income | 32.70 | 31.58 | 37.38 | 51.38 | 56.06 | 52.39 | 57.31 | 49.30 | 40.03 | 41.14 |
| Net Income | 24.38 | 23.85 | 21.56 | 32.23 | 35.54 | 34.74 | 38.03 | 33.37 | 26.83 | 26.65 |
| Shares Outstanding | 42.57 | 42.33 | 42.19 | 42.01 | 41.66 | 41.46 | 41.23 | 41.08 | 40.72 | 40.52 |
| Earnings Per Share | 0.57 | 0.56 | 0.51 | 0.76 | 0.85 | 0.83 | 0.91 | 0.80 | 0.65 | 0.65 |
| EPS Growth | 1.79% | 9.8% | -32.89% | -10.59% | 2.41% | -8.79% | 13.75% | 23.08% | 0% | - |
| Dividend Per Share | 0.25 | 0.50 | 0.58 | 0.80 | 0.80 | 0.79 | 0.76 | 0.76 | 0.76 | 0.74 |
| Dividend Growth | -50% | -13.04% | -28.13% | 0% | 1.27% | 3.95% | 0% | 0% | 2.7% | - |
| Operating Cash Flow | 35.83 | 34.78 | 41.36 | 37.22 | 42.81 | 38.26 | 44.44 | 42.45 | 22.46 | 29.73 |
| Capital Expenditures | -3.13 | -4.20 | -4.47 | -4.00 | -3.48 | -5.31 | -3.23 | -3.13 | -9.14 | -3.08 |
| Free Cash Flow | 32.70 | 30.58 | 36.89 | 33.22 | 39.33 | 32.96 | 41.20 | 39.32 | 13.32 | 26.65 |
| Cash & Equivalents | 62.40 | 60.76 | 58.07 | 48.23 | 50.97 | 44.05 | 45.28 | 32.59 | 24.63 | 38.88 |
| Total Debt | 75.82 | 50.18 | 54.65 | 58.36 | - | - | - | - | - | - |
| Net Cash / Debt | -13.43 | 10.58 | 3.43 | -10.13 | 50.97 | 44.05 | 45.28 | 32.59 | 24.63 | 38.88 |
| Assets | 325 | 251 | 250 | 252 | 183 | 177 | 177 | 161 | 155 | 155 |
| Liabilities | 135 | 75.96 | 80.19 | 85.56 | 17.41 | 15.90 | 21.70 | 18.63 | 16.97 | 17.28 |
| Book Value | 191 | 175 | 170 | 166 | 166 | 161 | 155 | 143 | 139 | 137 |
Company Profile
Company Details
| Full Name | Meridian Bioscience, Inc. |
| Country | United States |
| Employees | 660 |
| CEO | John Patrick Kenny |
Stock Information
| Ticker Symbol | VIVO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: VIVO |
Description
Meridian Bioscience, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.